At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 780 enrolled
Drug / intervention
Indacaterol/Glycopyrrolate +1 moredrug
Likely dose
Indacaterol/Glycopyrrolate 15.6 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
In Brief
A Phase 3 clinical trial evaluating Indacaterol/Glycopyrrolate and Placebo for COPD (Chronic Obstructive Pulmonary Disease). Completed, enrolled 780 participants across 16 sites.
Detailed Summary
The study hypothesis is that symptomatic current and former smokers with spirometric values within the normal range (post-bronchodilator FEV1/FVC≥0.70 and post-BD FVC ≥ 70% predicted will still derive symptomatic benefit from long-acting bronchodilator therapy even though they are excluded from current GOLD guideline recommendations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartAug 2017
Primary CompletionJul 2021
TodayJul 2026
First PostedAug 16, 2016
Enrollment StartAug 29, 2017
Primary CompletionJul 7, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.9 years ago
Interventions
Indacaterol/Glycopyrrolatedrug
27.5/15.6 mcg active indacaterol/glycopyrrolate
Placebodrug
27.5/15.6 mcg placebo